Literature DB >> 21506603

HCV-NS3/4A protease inhibitory iridoid glucosides and dimeric foliamenthoic acid derivatives from Anarrhinum orientale.

Riham Salah El Dine1, Azza R Abdel Monem, Ali M El-Halawany, Masao Hattori, Essam Abdel-Sattar.   

Abstract

Four new compounds were isolated from the methanol extract of the aerial parts of Anarrhinum orientale: 6'-O-cinnamoylmussaenosidic acid (1), 6'-O-cinnamoyl-8-O-(6'''-O-cinnamoylglucopyranosyl)mussaenosidic acid (2), (2E,6E)-8-{[(2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dienoyl]oxy}-2,6-dimethylocta-2,6-dienoic acid (3), and (2E,6E)-8-{[(2E,6E)-8-acetoxy-2,6-dimethylocta-2,6-dienoyl]oxy}-2,6-dimethylocta-2,6-dienoic acid (4). The known 8-O-cinnamoylmussaenosidic acid (5) was also identified. All five compounds were tested for inhibition of the hepatitis C virus (HCV) protease. Compounds 1 and 5 exhibited moderate activity, while 2 and 3 showed weak effects. No inhibitory activity on the human serine protease was observed for any of these compounds, which may infer the selectivity toward the viral protease. A computational docking study of the isolated compounds against HCV protease was used to formulate a hypothetical mechanism for the inhibitory activity of the active compounds on the enzymes tested.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506603     DOI: 10.1021/np100554h

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  2 in total

1.  Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition.

Authors:  Duozhi Chen; Jieyun Cai; Junjun Cheng; Chenxu Jing; Junlin Yin; Jiandong Jiang; Zonggen Peng; Xiaojiang Hao
Journal:  Sci Rep       Date:  2015-10-07       Impact factor: 4.379

2.  Antimicrobial, Cytotoxic, and Antioxidant Potential of a Novel Flavone "6,7,4'-Trimethyl Flavone" Isolated from Wulfenia amherstiana.

Authors:  Maria Kakar; Muhammad Usman Amin; Saad Alghamdi; Muhammad Umar Khayam Sahibzada; Nisar Ahmad; Naseem Ullah
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-08       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.